Research · Regulatory news

Orforglipron gains UK regulatory approval for type 2 diabetes

By Erik Jones · Aug 11, 2026 · 4 min read

The UK just became the first country in Europe to approve an oral GLP-1 pill for type 2 diabetes. On August 10, 2026, Britain’s medicines regulator, the MHRA, authorized orforglipron, sold as Foundayo, for adults with type 2 diabetes who are not yet reaching their blood sugar targets. This is a decision made for people, based on human clinical trials, not an early lab finding.

Here’s what that means and what it doesn’t.

What orforglipron is

Orforglipron belongs to a drug class called GLP-1 receptor agonists. You may already know this family by brand names like Ozempic or Mounjaro, which are injections. Orforglipron works the same way those drugs do: it copies the action of a gut hormone (GLP-1) that your body makes after eating, which tells your brain you’re full and helps your pancreas release insulin when blood sugar is high.

The difference that matters here is the form. Orforglipron is a pill, taken once a day, at any time, with no food or water rules. Most GLP-1 medicines require an injection and some require fasting or timing around meals. The UK’s regulator notes this is only the second oral GLP-1 approved in Britain (the first is oral semaglutide), and the first of either kind without food, water, or timing restrictions.

Dosing starts low and increases slowly: 0.8 mg, then step up through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg, with at least a month spent at each dose before moving to the next. That gradual schedule is standard practice for this drug class and is meant to reduce side effects as the body adjusts.

What the evidence actually shows

The MHRA’s decision rests on a multi-trial program called ACHIEVE, run by Eli Lilly, the drug’s maker. These were randomized controlled trials in people with type 2 diabetes, not animal studies and not a single uncontrolled report. A few of the headline results:

• In one trial (ACHIEVE-1), people whose diabetes wasn’t controlled by diet and exercise alone saw their HbA1c, the standard blood test for average blood sugar over about three months, drop by roughly 1.4 to 1.6 percentage points over 40 weeks.
• In a head-to-head trial against dapagliflozin, a widely used diabetes pill, orforglipron produced a larger HbA1c drop (1.3 to 1.7 points versus 0.8 for dapagliflozin), and up to 80% of patients on orforglipron got their HbA1c under 7%, a common treatment target.
• In a trial comparing it directly to oral semaglutide, orforglipron produced a bigger HbA1c reduction at the higher doses tested.

Those are real, measured outcomes in people with the condition, which is a meaningfully higher bar than the animal and cell-based research that often gets inflated in health reporting. The most commonly reported side effects in these trials were nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain, consistent with what’s seen across this entire drug class.

What this approval is not

It is not an NHS funding decision. Foundayo is authorized for sale, meaning a doctor can legally prescribe it, but it is not currently available free or subsidized through the NHS. The National Institute for Health and Care Excellence (NICE) has to separately evaluate whether the health service should pay for it, and that review has not concluded. For now, UK patients who want it need a private prescription from a qualified prescriber, and they’ll pay the private cost.

It is also not a statement that this drug is right for any particular person. Whether orforglipron suits someone depends on their medical history, other medications, and other clinical factors a prescriber has to weigh. This article is not medical advice, and it should not be read as a recommendation to start, stop, or switch any diabetes treatment. That conversation belongs with your own doctor or diabetes care team.

Why it matters beyond the UK

Regulatory approval in one country is not approval everywhere, and the FDA and other regulators have their own separate review processes still underway. But the UK being first in Europe to greenlight an oral GLP-1 for diabetes, on the strength of a full phase 3 trial program in actual patients, is a signal this drug class is maturing past its injectable-only phase. For people who have wanted the metabolic benefits of a GLP-1 drug but have avoided or struggled with needles, a once-daily pill with no meal-timing restrictions removes a real practical barrier, if and when it becomes affordable and accessible where they live.

What to watch next: whether NICE recommends NHS funding, and whether other regulators, including the FDA, follow the UK’s authorization for the diabetes indication specifically. We do not yet know the answer to either question, and nothing here should be read as a prediction that they will.

Primary source: MHRA’s own announcement, https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes. Coverage consulted: https://envigore.com/foundayo-pill-for-weight-management/ and https://www.delveinsight.com/report-store/type-2-diabetes-competitive-landscape-and-clinical-trial-analysis.

Not medical advice. Educational summary of published research. Last reviewed Oct 20, 2026.